Dr. Luke O'Neill
Professor Luke O’Neill was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he leads the Inflammation Research Group. He has a PhD in Pharmacology from the University of London and carried out Post-Doctoral research at Cambridge U.K. on the pro-inflammatory cytokine IL-1 and innate immune signaling. His research is in the area of the molecular basis to inflammatory diseases, with a particular interest in Toll-like receptors, inflammasomes and metabolic control of inflammatory cell signalling. He has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence and in 2014 the European Federation of Immunology Societies Medal. He was elected a member of EMBO in 2005. In 2016 he was named by Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in both Immunology and Pharmacology/Toxicology. He is a European Research Council Advanced Grant Holder and is co-founder of 2 Spin-out companies from his lab - Opsona Therapeutics, a drug development company working in the area of Toll-like receptors, and Inflazome, which is developing inhibitors of inflammasomes for inflammatory diseases. He was elected a Fellow of the Royal Society in 2016.